1. 1 Medicines & Healthcare Products Regulatory Authority. Safety of seroxat (paroxetine) in children and adolescents under 18 years - contraindication in the treatment of depressive illness - Epinet message from Professor G Duff, Chairman of Committee on Safety of Medicines (CSM). World Wide Web. Available at http://www.mhra.gov.uk/Safetyinformation/Safetywarningsalertsandrecalls/Safetywarningsandmessagesformedicines/CON2015704 (last accessed 16 September 2008).
2. 2 Medicines & Healthcare Products Regulatory Authority. Selective Serotonin Reuptake Inhibitors (SSRIs): overview of regulatory status and CSM advice relating to major depressive disorder (MDD) in children and adolescents including a summary of available safety and efficacy data. World Wide Web. Available at http://www.mhra.gov.uk/Safetyinformation/Safetywarningsalertsandrecalls/Safetywarningsandmessagesformedicines/CON019494 (last accessed 18 April 2007).
3. 3 US Food and Drug Administration. Relationship between psychotropic drugs and pediatric suicidality: review and evaluation of clinical data. World Wide Web. Available at http://www.fda.gov/ohrms/dockets/ac/04/briefing/2004-4065b1-10-TAB08-Hammads-Review.pdf (last accessed 9 May 2007).
4. The contribution of pharmacoepidemiology to the antidepressant-suicidality debate in children and adolescents;Bridge;Int Rev Psychiatry,2008